EFM
CMPX icon

E Fund Management’s Compass Therapeutics CMPX Stock Holding History

E Fund Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.7K Buy
26,808
+2,186
+9% +$6.45K ﹤0.01% 484
2026
Q1 		$130K Buy
+24,622
New +$142K ﹤0.01% 466

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

E Fund Management's CMPX Position: Q2 2026 in Review

E Fund Management increased its Compass Therapeutics (CMPX) stake by 8.9% in Q2 2026, buying an estimated $6.45K and bringing the position to 26,808 shares worth $58.7K. The position accounts for ﹤0.01% of the portfolio, ranked #484.

E Fund Management first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $130K in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • E Fund Management held 26,808 shares of Compass Therapeutics worth $58.7K as of Q2 2026.
  • E Fund Management bought 2,186 Compass Therapeutics shares in Q2 2026, an estimated $6.45K.
  • Compass Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #484 holding.
  • E Fund Management first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • E Fund Management's Compass Therapeutics position peaked at $130K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.